All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022
Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015 Source: Eur Respir J , 49 (4) 1602309; DOI: 10.1183/13993003.02309-2016 Year: 2017
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 1901467; 10.1183/13993003.01467-2019 Year: 2020
Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico Source: Eur Respir J, 51 (3) 1702267; 10.1183/13993003.02267-2017 Year: 2018
The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
Resistance rates of Mycobacterium tuberculosis to first-line antituberculosis drugs. Trends in Greece during the period 1991–2000 Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021
Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
Shorter treatment duration for selected patients with multidrug-resistant tuberculosis Source: Eur Respir J 2011; 37: 227-230 Year: 2011
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007